Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Revenue of Tarsus Pharmaceuticals, Inc. (TARS)
Revenue in 2023 (TTM): $17.45 M
According to Tarsus Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $17.45 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Tarsus Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $17.45 M | $15.85 M | $-142,281,000 | $-135,893,000 | $-135,893,000 |
| 2022 | $25.82 M | $24.86 M | $-59,127,000 | $-62,095,000 | $-62,091,000 |
| 2021 | $57.03 M | $54.95 M | $-10,579,000 | $-13,772,000 | $-13,827,000 |
| 2020 | $ | $-246,000 | $-26,902,000 | $-26,810,000 | $-26,811,000 |
| 2019 | $ | $-74,000 | $-3,930,000 | $-4,669,000 | $-4,670,000 |
| 2018 | $ | $-1,000 | $-1,349,000 | $-1,318,000 | $-1,319,000 |